Investigational drug · Phase 2
CT071
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Multiple Myeloma, Primary Plasma Cell Leukemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 27, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "CT071"
First trial start
2024
Apr 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CT071", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple Myeloma
- Primary Plasma Cell Leukemia
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "CT071" as an intervention, largest first.
- Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCLNot yet recruiting
CARsgen Therapeutics Co., Ltd.Industry
NCT06333509 · 166 participants (planned) · Start Apr 15, 2024 · Primary completion Jun 15, 2027
Drug: CT071 · For: Multiple Myeloma; Primary Plasma Cell Leukemia
- Study of CT071 Injection in RRMM or PPCLActive, not recruiting
Shanghai Changzheng HospitalAcademic, hospital or other
NCT05838131 · 20 participants · Start Apr 28, 2023 · Primary completion Jul 2025
Drug: Experimental: CAR-T cells Infusion · For: Multiple Myeloma; Primary Plasma Cell Leukemia
Sites: Shanghai, China
Shanghai Changzheng HospitalAcademic, hospital or other
NCT06407947 · 10 participants (planned) · Start Jun 6, 2024 · Primary completion Jun 3, 2027
Drug: Chimeric antigen receptor modified T cells Infusion · For: Multiple Myeloma
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial.
Jin L, Gu S, Ruan Q, et al. · Lancet Haematol 2025
Also in development for Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- GR1803Velinotamig specified specified days., CLN-803Phase 37 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
- JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Cilta-celJNJ-68284528Phase 36 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials
Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
- CevostamabRO7187797Phase 34 trials
Roche (Genentech) · Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.